Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00228592 · ClinicalTrials.gov registry record · Phase 2
HepeX-B in Post Hepatic Allografts for Treatment of End Stage Liver Disease Due to Hepatitis B Infection
A Phase 2 study, sponsored by Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
- Terminated
- Registry status
- Phase 2
- Development phase
NCT00228592: Clinical Trial Phase 2 study, sponsored by Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
NCT00228592 is a Phase 2 study that was terminated before completion, run by Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00228592, a Phase 2 study, was terminated before completion, sponsored by Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
- TERMINATED
- Registry status
- Phase 2
- Development phase
Study Summary
The purpose of this study is to compare the use of HepeX-B versus HBIg, two anti-viral drugs, in patients who have received liver transplants due to liver failure caused by Hepatitis B infection. Patients will be evaluated over a 6 month to 1.5 year period to evaluate whether or not the drugs prevent the Hepatitis B virus from infecting the new liver.
Interventions
- DRUG HepeX-B
- DRUG Hepatitis B Immune Globulin (HBIg)
Trial Details
| Field | Value |
|---|---|
| Est. Completion | 2005-08 |
| Phase | Phase 2 |
Sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)42 total trials
Why NCT00228592 stopped before completion
NCT00228592 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which HepeX-B is the first listed.
NCT00228592 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00228592 about?
NCT00228592 is a clinical study titled "HepeX-B in Post Hepatic Allografts for Treatment of End Stage Liver Disease Due to Hepatitis B Infection". The purpose of this study is to compare the use of HepeX-B versus HBIg, two anti-viral drugs, in patients who have received liver transplants due to liver failure caused by Hepatitis B infection. Patients will be evaluated over a 6 month to 1.5 year period to evaluate whether or not the drugs preven...
What is the current status of trial NCT00228592?
This trial is currently terminated. It is a Phase 2 study. Estimated completion is 2005-08.
What interventions are being tested in trial NCT00228592?
The interventions under investigation include: HepeX-B (DRUG), Hepatitis B Immune Globulin (HBIg) (DRUG).
Who is sponsoring clinical trial NCT00228592?
This trial is sponsored by Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), which has 42 total clinical trials registered on ClinicalTrials.gov.